Inventor · disambiguated record
Kandasamy Hariharan
Also filed as: HARIHARAN KANDASAMY
11 granted patents·37 pending applications·258 citations·filing 1999–2023
90Inventor score
Top patents by PatentIndex Score
48 records- 0194US7612178B2Anti-IGF-1R antibodies and uses thereofBIOGEN IDEC INC·Filed 2007·Granted Nov 3, 2009·24 cites·16 claims
- 0293US8147829B2Anti-IGR-1R antibodies and uses thereofHARIHARAN KANDASAMY·Filed 2009·Granted Apr 3, 2012·41 cites·22 claims
- 0392US6897044B1Production of tetravalent antibodiesBIOGEN IDEC INC·Filed 1999·Granted May 24, 2005·133 cites·32 claims
- 0489US6998125B2Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesisBIOGEN IDEC INC·Filed 2001·Granted Feb 14, 2006·25 cites·19 claims
- 0588US10428145B2PD-1 binding proteins and methods of use thereofCELGENE CORP·Filed 2016·Granted Oct 1, 2019·10 cites·155 claims
- 0687US7319139B2TAG-72 specific CH2 domain deleted antibodiesBIOGEN IDEC INC·Filed 2002·Granted Jan 15, 2008·25 cites·22 claims
- 0771US2008213260A1Use of cd23 antagonists for the treatment of neoplastic disordersBIOGEN IDEC INC·Filed 2007·Application pending·0 cites
- 0871US2008213167A1Use of cd23 antagonists for the treatment of neoplastic disordersBIOGEN IDEC INC·Filed 2007·Application pending·0 cites
- 0970US2023272076A1PD-1 Binding Proteins and Methods of Use ThereofCELGENE CORP·Filed 2022·Application pending·0 cites
- 1069US2008226626A1Immunoregulatory antibodies and uses thereofBIOGEN IDEC INC·Filed 2007·Application pending·0 cites
- 1166US2006171950A1Use of cd23 antagonists for the treatment of neoplastic disordersBIOGEN IDEC INC·Filed 2006·Application pending·0 cites
- 1265US2008171056A1Use of cd23 antagonists for the treatment of neoplastic disordersBIOGEN IDEC INC·Filed 2007·Application pending·0 cites
- 1365US2024075133A1Methods and compositions for reduction of immunogenicityCELGENE CORP·Filed 2023·Application pending·0 cites
- 1463US2004137014A1Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesisBIOGEN IDEC INC·Filed 2003·Application pending·0 cites
- 1563US2006286101A1Use of CD23 Antagonists for the Treatment of Neoplastic DisordersBIOGEN IDEC INC·Filed 2006·Application pending·0 cites
- 1662US2008213168A1Use of cd23 antagonists for the treatment of neoplastic disordersBIOGEN IDEC INC·Filed 2007·Application pending·0 cites
- 1762US2022324991A1Bcma-binding antibodies and uses thereofCELGENE CORP·Filed 2022·Application pending·0 cites
- 1861US2020255525A1Pd-1 binding proteins and methods of use thereofCELGENE CORP·Filed 2019·Application pending·0 cites
- 1961US2005123540A1Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applicationsBIOGEN IDEC INC·Filed 2004·Application pending·0 cites
- 2061US2008227198A1Immunoregulatory antibodies and uses thereofBIOGEN IDEC INC·Filed 2007·Application pending·0 cites
- 2161US2006286100A1Use of CD23 Antagonists for the Treatment of Neoplastic DisordersBIOGEN IDEC INC·Filed 2006·Application pending·0 cites
- 2260US2021371522A1Cd47 antibodies and methods of use thereofCELGENE CORP·Filed 2021·Application pending·0 cites
- 2360US2003211107A1Use of CD23 antagonists for the treatment of neoplastic disordersFiled 2002·Application pending·0 cites
- 2459US12428488B2Engineering of an antibody for tumor-selective binding of CD47CELGENE CORP·Filed 2020·Granted Sep 30, 2025·0 cites·17 claims
- 2559US2003103971A1Immunoregulatory antibodies and uses thereofFiled 2002·Application pending·0 cites
- 2657US12084499B2SIRP-α binding proteins and methods of use thereofCELGENE CORP·Filed 2023·Granted Sep 10, 2024·0 cites·31 claims
- 2755US2006153848A1Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesisHANNA NABIL·Filed 2005·Application pending·0 cites
- 2853US2020330590A1Methods and compositions for reduction of immunogenicityCELGENE CORP·Filed 2018·Application pending·0 cites
- 2952US2023365681A1Bispecific antibody treatment of lymphoid malignant neoplasm conditionsCELGENE CORP·Filed 2021·Application pending·0 cites
- 3052US2005158828A1Production of tetravalent antibodiesBIOGEN IDEC INC·Filed 2004·Application pending·0 cites
- 3151US2002028178A1Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applicationsFiled 2001·Application pending·0 cites
- 3250US2009130105A1Compositions that bind multiple epitopes of igf-1rBIOGEN IDEC INC·Filed 2008·Application pending·0 cites
- 3350US2009092614A1Anti-IGF-1R Antibodies and Uses ThereofBIOGEN IDEC INC·Filed 2008·Application pending·0 cites
- 3450US2003180290A1Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapiesIDEC PHARMA CORP·Filed 2002·Application pending·0 cites
- 3549US2009291088A1Therapeutic combinations of anti-igf-1r antibodies and other compoundsBIOGEN IDEC INC·Filed 2009·Application pending·0 cites
- 3649US2013183288A1Non-fucosylated antibodiesREFF MITCHELL·Filed 2008·Application pending·0 cites
- 3748US11401336B2BCMA-binding antibodies and uses thereofCELGENE CORP·Filed 2019·Granted Aug 2, 2022·0 cites·18 claims
- 3848US2010189716A1Treatment of hodgkins lymphomaBIOGEN IDEC INC·Filed 2008·Application pending·0 cites
- 3948US2003180292A1Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapyIDEC PHARMACEUTICALS·Filed 2002·Application pending·0 cites
- 4047US2020255515A1Cd47 antibodies and methods of use thereofCELGENE CORP·Filed 2017·Application pending·0 cites
- 4146US11591390B2SIRP-α binding proteins and methods of use thereofCELGENE CORP·Filed 2019·Granted Feb 28, 2023·0 cites·24 claims
- 4246US2007065436A1Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapiesBIOGEN IDEC INC·Filed 2006·Application pending·0 cites
- 4345US2007009519A1Immunoregulatory Antibodies and Uses ThereofBIOGEN IDEC INC·Filed 2006·Application pending·0 cites
- 4444US2001018041A1Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapyIDEC PHARMA CORP·Filed 2001·Application pending·0 cites
- 4543US2002159996A1Use of CD23 antagonists for the treatment of neoplastic disordersFiled 2001·Application pending·0 cites
- 4642US2010203010A1Modulation of tumor microenvironmentBIOGEN IDEC INC·Filed 2008·Application pending·0 cites
- 4739US2002006404A1Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applicationsIDEC PHARMA CORP·Filed 2001·Application pending·0 cites
- 4837US11427632B2Antibodies with low immunogenicity and uses thereofCELGENE CORP·Filed 2017·Granted Aug 30, 2022·0 cites·15 claims
Join the waitlist — get patent alerts
Get an alert when Kandasamy Hariharan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →